CanBas Co

CanBas Co Liabilities

The The Liabilities of CanBas Co (4575.T) as of Oct 18, 2026 is 134.71 M JPY. In the previous year, The Liabilities was 107.00 M JPY — a change of 25.90% (higher).

Liabilities

134.71 MJPY

YoY

25.90%

Last updated:

In 2026, CanBas Co's total liabilities amounted to 134.71 M JPY, a 25.90% difference from the 107.00 M JPY total liabilities in the previous year.

The CanBas Co Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Liabilities
Date
Liabilities
Jan 1, 2019
219.08 M JPY
Jan 1, 2020
1.03 B JPY
Jan 1, 2021
857.64 M JPY
Jan 1, 2022
540.02 M JPY
Jan 1, 2023
153.85 M JPY
Jan 1, 2024
91.99 M JPY
Jan 1, 2025
107.00 M JPY
Jan 1, 2026
134.71 M JPY
The CanBas Co Liabilities history
YEARLiabilitiesYoY
134.71 MJPY+25.90%
107.00 MJPY+16.32%
91.99 MJPY-40.21%
153.85 MJPY-71.51%
540.02 MJPY-37.03%
857.64 MJPY-16.44%
1.03 BJPY+368.49%
219.08 MJPY+40.12%
156.35 MJPY+136.23%
66.19 MJPY+73.56%
38.14 MJPY+15.27%
33.08 MJPY-47.33%
62.81 MJPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

CanBas Co Stock analysis

What does CanBas Co do? CanBas Co Ltd is a biotechnology company based in Numazu-shi, Japan, operating within the healthcare sector. The company has a small team of 12 employees and went public on September 17, 2009, with its ticker listed as 4575.T and ISIN JP3244570002. Its primary focus is on anticancer drug discovery research, which includes developing drug discovery concepts, selecting candidate compounds through method-based approaches, conducting simple animal studies, and analyzing basic data on anticancer drug candidates entering development. Additionally, CanBas engages in early clinical development activities, such as preclinical studies required before submitting applications for clinical trials and conducting the initial phases of clinical trials. The company maintains a website at https://www.canbas.co.jp/ for further information. CanBas operates as a private entity with a minimal workforce, emphasizing research and development in the early stages of anticancer drug development. It does not provide details on specific products, acquisitions, or financial figures beyond its IPO date and employee count. The company's headquarters are located in Numazu-shi, Shizuoka Prefecture, Japan, and it is listed on the Tokyo Stock Exchange. Its operations are centered around foundational research in oncology, aiming to contribute to the discovery and development of new anticancer treatments. CanBas Co is one of the most popular companies on Eulerpool.

Liabilities Details

Assessing CanBas Co's Liabilities

CanBas Co's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating CanBas Co's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing CanBas Co's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

CanBas Co's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in CanBas Co’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about CanBas Co stock

The Liabilities of CanBas Co is 134.71 M JPY in 2026.

The Liabilities of CanBas Co changed from 107.00 M JPY to 134.71 M JPY, representing a 25.90% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Liabilities CanBas Co since 2006 – with annual values, charts, and detailed analysis.

The Liabilities's JPY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Liabilities's CanBas Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — CanBas Co

All Key Metrics — CanBas Co